CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY

Efficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen jo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. S. Shirinsky, O. A. Polovnikova, N. Yu. Kalinovskaya, I. V. Shirinsky
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	autoimmune disorders rheumatoid arthritis ppar fenofibrate Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/ec66ce617207447990c77f175285ec70
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec66ce617207447990c77f175285ec70
record_format	dspace
spelling	oai:doaj.org-article:ec66ce617207447990c77f175285ec702021-11-18T08:03:37ZCLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY1563-06252313-741X10.15789/1563-0625-2014-1-71-80https://doaj.org/article/ec66ce617207447990c77f175285ec702014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/27https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XEfficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen joints, and slower ESR in fenofibrate group (n = 33) as compared with control group (n = 17). Frequency of EULAR and ACR20 responses was 4 times higher in fenofibrate group. Clinical effect was accompanied by decrease in serum immunological markers of atherosclerosis (IL-6 and CRP), diminished total cholesterol andtriglycerides. In summary, PPARα agonists may represent an example of a “hub” treatment for rheumatoid arthritis, with pleiotropic effects directed at inflammatory activity and increased risk of other comorbidites, including atherosclerosis.V. S. ShirinskyO. A. PolovnikovaN. Yu. KalinovskayaI. V. ShirinskySPb RAACIarticleautoimmune disordersrheumatoid arthritispparfenofibrateImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 16, Iss 1, Pp 71-80 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	autoimmune disorders rheumatoid arthritis ppar fenofibrate Immunologic diseases. Allergy RC581-607
spellingShingle	autoimmune disorders rheumatoid arthritis ppar fenofibrate Immunologic diseases. Allergy RC581-607 V. S. Shirinsky O. A. Polovnikova N. Yu. Kalinovskaya I. V. Shirinsky CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
description	Efficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen joints, and slower ESR in fenofibrate group (n = 33) as compared with control group (n = 17). Frequency of EULAR and ACR20 responses was 4 times higher in fenofibrate group. Clinical effect was accompanied by decrease in serum immunological markers of atherosclerosis (IL-6 and CRP), diminished total cholesterol andtriglycerides. In summary, PPARα agonists may represent an example of a “hub” treatment for rheumatoid arthritis, with pleiotropic effects directed at inflammatory activity and increased risk of other comorbidites, including atherosclerosis.
format	article
author	V. S. Shirinsky O. A. Polovnikova N. Yu. Kalinovskaya I. V. Shirinsky
author_facet	V. S. Shirinsky O. A. Polovnikova N. Yu. Kalinovskaya I. V. Shirinsky
author_sort	V. S. Shirinsky
title	CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
title_short	CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
title_full	CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
title_fullStr	CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
title_full_unstemmed	CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
title_sort	clinical efficacy and safety of peroxisome proliferator-activated receptor alpha agonists in rheumatoid arthritis: an open-label controlled study
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/ec66ce617207447990c77f175285ec70
work_keys_str_mv	AT vsshirinsky clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy AT oapolovnikova clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy AT nyukalinovskaya clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy AT ivshirinsky clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy
_version_	1718422578068979712

CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY

Ejemplares similares